

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
Q5145	Abrilada	adalimumab-afzb	Y	N	N	N	N
J3262	Actemra IV	tocilizumab		N	N	N	N
J0791	Adakveo	crizanlizumab-tmca		N	Y	N	N
J9042	Adcetris	brentuximab vedotin		N	Y	N	N
J7171	Adzynma	ADAMTS13, recombinant-krhn	Y	N	N	N	N
Q5150	Ahzantive	aflibercept-mrbb		N	N	N	N
J1931	Aldurazyme	laronidase		Y	N	N	N
J1552	Alyglo	intravenous immune globulin	Y	N	N	N	Y
Q5126	Alymsys	bevacizumab-maly		N	Y	N	N
J3590	Amjevita	adalimumab-atto	Y	N	N	N	N
J1426	Amondys-45	casimersen	Y	Y	N	N	N
J0225	Amvuttra	vutrisiran		Y	N	N	N
J9028	Anktiva	nogapendekin alfa inbakicept-pmln		N	N	N	N
J2277	Aphexda	motixafortide		N	N	N	N
J0881	Aranesp	darbepoetin	Y	N	N	N	N
J2793	Arcalyst	rilonacept	Y	N	N	N	N
J9302	Arzerra	ofatumumab		N	N	N	N
J1554	Asceniv	intravenous immune globulin	Y	N	N	N	Y
J9118	Asparlas	calaspargase pegol-mknl		N	N	N	N
J3590	Aukelso	denosumab-kyqq	Y	N	N	N	N
J9035	Avastin	bevacizumab		N	Y	N	N
C9257	Avastin	bevacizumab		N	N	N	N
J3145	Aveed	testosterone undecanoate		N	N	N	N
Q5121	Avsola	infliximab-axxq	Y	N	Y	N	N
Q5156	Avtozma IV	tocilizumab-anoh		N	N	N	N
J9999	Avzivi	bevacizumab-tnjn		N	Y	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9023	Bavencio	avelumab		N	N	Y	N
J9999	Blenrep	belantamab mafodotin-blmf		Y	N	N	N
J9174	Beizray	docetaxel		N	N	N	N
J9032	Beleodaq	belinostat		N	N	N	N
J0490	Benlysta	belimumab		N	N	N	N
J0597	Beriner	c1 inhibitor (human)	Y	Y	N	N	N
J9229	Besponsa	inotuzumab ozogamicin		N	N	N	N
J3590	Bildyos	denosumab-nxxp		N	N	N	N
J3590	Bilprevda	denosumab-nxxp		N	N	N	N
J1556	Bivigam	intravenous immune globulin	Y	N	N	N	Y
J9382	Bizengri	zenocutuzmab		N	N	N	N
J9382	Bizengri	zenocutuzumab-zbco		N	N	N	N
Q5152	Bkemv	eculizumab-aeeb		Y	N	N	N
J9039	Blincyto	blinatumomab		Y	N	N	N
Q5158	Bomynta	denosumab-bnht	Y	N	N	N	N
J9054	Boruzu	bortezomib	Y	N	N	N	N
J3590	Bosaya	denosumab-kyqq	Y	N	N	N	N
J0585	Botox	onabotulinumtoxin	Y	N	N	N	N
J2329	Briumvi	ublituximab-xiiy	Y	N	N	N	N
J9064	Cabazitaxel	cabazitaxel (Sandoz)		N	Y	N	N
C9047	Cablivi	caplacizumab	Y	N	N	N	N
J1952	Camcevi	leuprolide mesylate (for depot emulsion)	Y	N	N	N	N
J3490	Camcevi ETM	leuprolide acetate		N	N	N	N
J1786	Cerezyme	imiglucerase		N	N	N	N
J0717	Cimzia	certolizumab pegol	Y	N	N	N	N
J2786	Cinqair	reslizumab		N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J0598	Cinryze	c1 inhibitor (human)	Y	Y	N	N	N
J9286	Columvi	glofitamab-gxbm		Y	N	N	N
Q5158	Conexence	denosumab-bnht	Y	N	N	N	N
J1448	Cosela	trilaciclib		N	N	N	N
J3247	Cosentyx IV	secukinumab		N	N	N	N
J0584	Crysvita	burosumab-twxa	Y	N	N	N	N
J1551	Cutaquig	subcutaneous immune globulin	Y	N	N	N	Y
J1555	Cuvitru	subcutaneous immune globulin	Y	N	N	N	Y
Q5143	Cyltezo	adalimumab-adbm	Y	N	N	N	N
J9308	Cyramza	ramucirumab		N	N	N	N
J9348	Danyelza	naxitamab-gqgk		N	N	N	N
J9145	Darzalex	daratumumab		N	N	N	N
J9144	Darzalex Faspro	daratumumab+hyaluronidase-fihj		N	N	N	N
J9011	Datroway	datopotamab deruxtecan-dlnk		N	N	N	N
J0589	Daxxify	daxibotulinumtoxinA	Y	N	N	N	N
Q5158	Denosumab-BNHT	denosumab-bnht		N	N	N	N
Q5159	Denosumab-DSSB	denosumab-dssb		N	N	N	N
J7318	Durolane	hyaluronan or derivative		N	N	N	N
J7351	Durysta	bimatoprost implant		N	N	N	N
J0586	Dysport	abobotulinumtoxina	Y	N	N	N	N
J9063	Elahere	mirvetuximab soravtansine-gynx		N	N	N	N
J1743	Elaprase	idursulfase		Y	N	N	N
J3060	ElELYso	taliglucerase alfa		N	N	N	N
J2508	Elfabrio	pegunigalsidase-iwxj	Y	N	N	N	N
J9217	Eligard	leuprolide acetate (for depot suspension)	Y	N	N	N	N
J1323	Elrexfio	elranatamab-bcmm		Y	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9269	Elzonris	tagraxofusp-erzs		N	N	N	N
C9151	Empaveli	pegcetacoplan	Y	Y	N	N	N
J7799	Empaveli	pegcetacoplan	Y	Y	N	N	N
C9151	Empaveli	pegcetacoplan	Y	N	N	N	N
J9176	Empliciti	elotuzumab		N	N	N	N
J9326	Emrelis	telisotuzumab vedotin-tllv		N	N	N	N
J1438	Enbrel	etanercept	Y	N	N	N	N
J9358	Enhertu	fam-trastuzumab deruxtecan-nxki		N	Y	N	N
J1302	Enjaymo	sutimlimab-jome		Y	N	N	N
J3380	Entyvio	vedolizumab	Y	N	N	N	N
Q5149	Enzeevu	aflibercept-abzv		N	N	N	N
J9321	Epkinly	epcoritamab-bysp		Y	N	N	N
Q5151	Epysqli	eculizumab-aagh		Y	N	N	N
J9019	Erwinase	crisantaspase		N	N	N	N
J7323	Euflexxa	hyaluronan or derivative		N	N	N	N
J3111	Evenity	romosozumab-aqqg	Y	N	N	N	N
J1305	Evkeeza	evinacumab-dgnb		Y	N	N	N
J3590	Exdensusr	depemokimab-ulaa	Y	N	N	N	N
J1428	Exondys-51	eteplirsen	Y	Y	N	N	N
J0180	Fabrazyme	agalsidase beta	Y	N	N	N	N
J0517	Fasenra	benralizumab	Y	N	N	N	N
J1951	Fensolvi	leuprolide acetate (for depot suspension)	Y	N	N	N	N
J1744	Firazyr	icatibant	Y	Y	N	N	N
J9155	Firmagon	degarelix	Y	N	N	N	N
J1572	Flebogamma	intravenous immune globulin	Y	N	N	N	Y
J1434	Focinvez IV	fosaprepitant	Y	N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9331	Fyarro	sirolimus-albumin-bound	Y	Y	N	N	N
J9210	Gamifant	emapalumab-lzsg	Y	Y	N	N	N
J1569	Gammagard Liquid	intravenous immune globulin	Y	N	N	N	Y
J1599	Gammagard Liquid ERC	immune globulin infusion (human) 10%		N	N	N	Y
J3590	Gammagard Liquid ERC	immune globulin infusion (human) 10%		N	N	N	Y
J1566	Gammagard S/D	immune globulin	Y	N	N	N	Y
J1561	Gammaked	intravenous immune globulin	Y	N	N	N	Y
J1557	Gammaplex	intravenous immune globulin	Y	N	N	N	Y
J1561	Gamunex-C	intravenous immune globulin	Y	N	N	N	Y
J9301	Gazyva	obinutuzumab		N	N	N	N
J7326	Gel-One	hyaluronan or derivative		N	N	N	N
J7328	Gelsyn-3	hyaluronan or derivative		N	N	N	N
J7320	GenVisc 850	hyaluronan or derivative		N	N	N	N
J0223	Givlaari	givosiran		Y	Y	N	N
J3590	Hadlima	adalimumab-bwwd	Y	N	N	N	N
J0599	Haegarda	C1 Esterase Inhibitor Subcutaneous [Human]		Y	N	N	N
J9179	Halaven	eribulin		N	N	N	N
J9248	Hepzato	melphalan		N	N	N	N
J9355	Herceptin	trastuzumab		N	Y	N	N
J9356	Herceptin Hylecta	trastuzumab-hyaluronidase-oysk		N	N	N	N
Q5146	Hercessi	trastuzumab-strf		N	N	N	N
Q5113	Herzuma	trastuzumab-pkrb		N	N	N	N
J1559	Hizentra	subcutaneous immune globulin	Y	N	N	N	Y
Q5140	Hulio	adalimumab-fkjp	Y	N	N	N	N
J0139	Humira	adalimumab	Y	N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J7321	Hyalgan	hyaluronan or derivative		N	N	N	N
J7322	Hymovis	hyaluronan or derivative		N	N	N	N
J7322	Hymovis One	hyaluronan or derivative		N	N	N	N
J1575	Hyqvia	subcutaneous immune globulin	Y	N	N	N	Y
J3590	Hyrimoz	adalimumab-adaz	Y	N	N	N	N
Q5144	Idacio	adalimumab-aacf	Y	N	N	N	N
J7355	Idose TR	travoprost intracameral implant		N	N	N	N
J0638	Ilaris	canakinumab	Y	N	N	N	N
J3245	Ilumya	tildrakizumab-asmn	Y	N	N	N	N
J3590	Imaavy	nipocalimab-aahu		N	N	N	N
J9026	Imdelltra	tarlatamab-dlle		N	N	N	N
J9173	Imfinzi	durvalumab		N	N	Y	N
J9347	Imjudo	tremelimumab-actl		N	N	N	N
J9325	Imlygic	talimogene laherparepvec		N	N	N	N
Q5098	Imuldosa IV	ustekinumab-srlf	Y	N	N	N	N
Q5098	Imuldosa SC	ustekinumab-srlf	Y	N	N	N	N
Q5103	Inflectra	infliximab-dyyb	Y	N	Y	N	N
J1745	infliximab	infliximab	Y	N	Y	N	N
J9999	Inlexzo	gemcitabine		N	N	N	N
J1599; J1566	Intravenous Immune Globulin	intravenous immune globulin		N	N	N	Y
J9319	Istodax	romidepsin		N	N	N	N
J2782	Izervay	avacincaptad pegol		N	N	N	N
J9281	Jelmyto	mitomycin		N	N	N	N
J9272	Jemperli	dostarlimab-gxly		N	N	N	N
J9043	Jevtana	cabazitaxel		N	Y	N	N
J9999	Jobevne	bevacizumab-nwgd		N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
Q5136	Jubbonti	denosumab-bbdz	Y	N	N	N	N
J9354	Kadcyla	ado-trastuzumab emtansine		N	Y	N	N
J1290	Kalbitor	ecallantide		Y	N	N	N
Q5117	Kanjinti	trastuzumab-anns		N	N	N	N
J2840	Kanuma	sebelipase alfa		N	N	N	N
J9271	Keytruda	pembrolizumab		N	N	Y	N
J9999	Keytruda QLEX	pembrolizumab and berahyaluronidase alfa-pmph		N	N	N	N
J9274	Kimmtrak	tebentafusp-tebn		N	N	N	N
J0175	Kisunla	donanemab-azbt	Y	N	N	N	N
J2507	Krystexxa	pegloticase		Y	N	N	N
J9047	Kyprolis	carfilzomib		N	N	N	N
J9999	Kyxata	carboplatin		N	N	N	N
J0217	Lamzedo	velmanase alfa-tycv		Y	N	N	N
J3590	Lasix Onyu	furosemide injection	Y	N	N	N	N
J0202	Lemtrada	alemtuzumab		N	N	N	N
J0174	Leqembi	lecanemab-irmb	Y	N	N	N	N
J3590	Leqembi IQLIK	lecanemab-irmb		N	N	N	N
J1306	Leqvio	inclisiran	Y	N	N	N	N
J1954	Leuprolide Acetate	leuprolide acetate (for depot suspension) (cipla)	Y	N	N	N	N
J9218	Leuprolide Acetate	leuprolide acetate (for depot suspension) (cipla)	Y	N	N	N	N
J9119	Libtayo	cemiplimab-rwlc		N	N	N	N
J3263	Loqtorzi	toripalimab-tpzi		N	N	N	N
J0221	Lumizyme	alglucosidase alfa		Y	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9350	Lunsumio	mosunetuzumab-axgb		N	N	N	N
J9999	Lunsumio Velo	mosunetuzumab-axgb		N	N	N	N
J9217	Lupron Depot	leuprolide acetate (for depot suspension)	Y	N	N	N	N
J1950	Lupron Depot-Ped	leuprolide acetate (for depot suspension)	Y	N	N	N	N
J9161	Lymphir	denileukin diftiox-cxdl		Y	N	N	N
J9999	Lynozytic	linvoseltamab		Y	N	N	N
J9353	Margenza	margetuximab-cmkb		N	N	N	N
J3397	Mepsevii	vestronidase alfa-vjkb		Y	N	N	N
J9349	Monjuvi	tafasitamab-cxix	Y	N	N	N	N
J7327	Monovisc	hyaluronan or derivative		N	N	N	N
Q5107	Mvasi	bevacizumab-awwb		N	Y	N	N
J9203	Mylotarg	gemtuzumab ozogamicin		N	N	N	N
J0587	Myobloc	rimabotulinumtoxinb	Y	N	N	N	N
J1458	Naglazyme	galsulfase		Y	N	N	N
J0219	Nexviazyme	avalglucosidase alfa-ngpt		Y	N	N	N
J9038	Niktimvo	axatilimab-csfr		N	N	N	N
J2802	Nplate	romiplostim		N	N	N	N
J2182	Nucala	mepolizumab	Y	N	N	N	N
J1809	Nulibry	fosdenopterin		N	N	N	N
J2350	Ocrevus	ocrelizumab	Y	N	N	N	N
J2351	Ocrevus Zunovo	ocrelizumab and hyaluronidase-ocsq	Y	N	N	N	N
J1568	Octagam	intravenous immune globulin	Y	N	N	N	Y
Q5114	Ogivri	trastuzumab-dkst		N	N	N	N
Q5154	Omlyclo	omalizumab-igec		N	N	N	N
J2267	OmvoH IV	mirikizumab-mrkz	Y	N	N	N	N
J2267	OmvoH SQ	mirikizumab-mrkz	Y	N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9205	Onivyde	irinotecan liposome		N	N	N	N
J0222	Onpattro	patisiran		Y	N	N	N
Q5112	Ontruzant	trastuzumab-dttb		N	N	N	N
J9299	Opdivo	nivolumab		N	N	Y	N
J9289	Opdivo Qvantig	nivolumab and hyaluronidase-nvhy		N	N	N	N
J9298	Opdualag	nivolumab/relatlimab-rmbw		N	N	N	N
Q5153	Opuviz	aflibercept-yszy		N	N	N	N
J0129	Orencia IV	abatacept	Y	N	N	N	N
J0129	Orencia SQ	abatacept	Y	N	N	N	N
J7324	Orthovisc	hyaluronan or derivative		N	N	N	N
Q5157	Osenvelt	denosumab-bmwo	Y	N	N	N	N
Q5159	Ospomyv	denosumab-dssb	Y	N	N	N	N
Q9999	Otulfu IV	ustekinumab-aauz	Y	N	N	N	N
Q9999	Otulfu SQ	ustekinumab-aauz	Y	N	N	N	N
J0224	Oxlumo	lumasiran		Y	N	N	N
J9177	Padcev	enfortumab vedotin-ejfv		N	Y	N	N
J1576	Panzyga	intravenous immune globulin	Y	N	N	N	Y
J0208	Pedmark	sodium thiosulfate		N	N	N	N
J9304	Pemfexy	pemetrexed		N	N	N	N
J9999	Penpulimab-kcqx	Penpulimab-kcqx		N	N	N	N
J9306	Perjeta	pertuzumab		N	N	N	N
J9316	Phesgo	Pertuzumab, trastuzumab, hyaluronidase-zzxf		N	N	N	N
J1307	Piasky	crovalimab-akkz		Y	N	N	N
J9309	Polivy	polatuzumab vedotin-piiq		N	N	N	N
J1203	Pombiliti	cipaglucosidase alfa-atga		Y	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9295	Portrazza	necitumumab		N	N	N	N
J9204	Poteligeo	mogamulizumab-kpkc		Y	N	N	N
J1459	Privigen	intravenous immune globulin	Y	N	N	N	Y
Q4081	Procrit	epoetin alfa	Y	N	N	N	N
J0885	Procrit/Epogen	epoetin alfa	Y	N	N	N	N
J0897	Prolia	denosumab	Y	N	N	N	N
Q9997	Pyzchiva IV	ustekinumab-ttwe	Y	N	N	N	N
Q9996	Pyzchiva SQ	ustekinumab-ttwe	Y	N	N	N	N
J1304	Qalsody	tofersen		N	N	N	N
J7174	Qfitlia	fitusiran	Y	N	N	N	N
J1599	Qivigy	immune globulin infusion (human) 10%		N	N	N	N
J1301	Radicava	edaravone	Y	N	N	N	N
J0896	Reblozyl	luspatercept-aamt		N	Y	N	N
J1745	Remicade	infliximab	Y	N	Y	N	N
J3285	Remodulin	treprostinil	Y	N	N	N	N
Q5104	Renflexis	infliximab-abda	Y	N	Y	N	N
J3590	Revcovi	elapeademase-lvlr	Y	N	N	N	N
Q5123	Riabni	rituximab-arrx		N	Y	N	N
J9312	Rituxan	rituximab		N	Y	N	N
J9311	Rituxan Hycela	rituximab and hyaluronidase human		N	N	N	N
J9318	Romidepsin	romidepsin		N	N	N	N
J9319	Romidepsin	romidepsin		N	N	N	N
J0596	Ruconest	c1 esterase inhibitor [recombinant]	Y	Y	N	N	N
Q5119	Ruxience	rituximab-pvvr		N	Y	N	N
J9061	Rybrevant	amivantamab-vmjw	Y	N	N	N	N
J9999	Rybrevant Faspro	amivantamab and hyaluronidase-lpuj		N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
J9021	Rylaze	asparaginase erwinia chrysanthemi recombinant-rywn		N	N	N	N
J2998	Ryplazim	plasminogen, human-tvmh	Y	N	N	N	N
J9333	Rystiggo	rozanolixizumab-noli		Y	N	N	N
J0870	Rytelo	imetelstat	Y	N	N	N	N
J9361	Ryzneuta	efbemalenograstim alfa-vuxw	Y	N	N	N	N
J0491	Saphnelo	anifrolumab-fnia		N	N	N	N
J9227	Sarclisa	isatuximab-irfc		N	N	N	N
J7352	Scenesse	afamelanotide		N	N	N	N
Q9998	Selarsdi IV	ustekinumab-aekn	Y	N	N	N	N
Q9998	Selarsdi SQ	ustekinumab-aekn	Y	N	N	N	N
J2502	Signifor LAR	pasireotide long acting		N	N	N	N
Q5142	Simlandi	adalimumab-ryvk	Y	N	N	N	N
J1602	Simponi_ARIA	golimumab	Y	N	Y	N	N
J2327	Skyrizi IV	risankizumab-rzaa	Y	N	N	N	N
J7331	Sodium hyaluronate	Sodium Hyaluronate		N	N	N	N
J1299	Soliris	eculizumab		Y	N	N	N
J3590	Somavert	pegvisomant	Y	N	N	N	N
J1747	Spevigo IV	spesolimab-sbzo	Y	N	N	N	N
J1747	Spevigo SQ	spesolimab-sbzo	Y	N	N	N	N
J2326	Spinraza	nusinersen		Y	N	N	N
S0013	Spravato	esketamine	Y	N	N	N	N
J3590	Starjemza IV	ustekinumab-hmny	Y	N	N	N	N
J3590	Starjemza SQ	ustekinumab-hmny	Y	N	N	N	N
J3358	Stelara IV	ustekinumab		N	N	N	N
J3357	Stelara SQ	ustekinumab	Y	N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
Q5099	Steqeyma IV	ustekinumab-stba	Y	N	N	N	N
Q5099	Steqeyma SQ	ustekinumab-stba	Y	N	N	N	N
Q5157	Stoboclo	denosumab-bmwo	Y	N	N	N	N
90284; J3590	Subcutaneous Immune Globulir	subcutaneous immune globulin		N	N	N	Y
J1961	Sunlenca	lenacapavir	Y	N	N	N	N
J7321	Supartz	hyaluronan or derivative		N	N	N	N
J7321	Supartz FX	hyaluronan or derivative		N	N	N	N
J9226	Supprelin LA	histrelin		N	N	N	N
J2781	Syfovre	pegcetacoplan		N	N	N	N
J2860	Sylvant	siltuximab		N	N	N	N
J7331	Synojoynt	hyaluronan or derivative		N	N	N	N
J7325	Synvisc	hyaluronan or derivative		N	N	N	N
J7325	Synvisc One	hyaluronan or derivative		N	N	N	N
J3055	Talvey	talquetamab-tgvs		Y	N	N	N
J9022	Tecentriq	atezolizumab		N	N	Y	N
J9024	Tecentriq Hybreza	atezolizumab-hyaluronidase-tqjs		N	N	N	N
J9380	Tecvayli	teclistamab-cqyv		Y	N	N	N
J3241	Tepezza	teprotumumab-trbw	Y	Y	Y	N	N
J3490	Testopel	testosterone pellets		N	N	N	N
S0189	Testopel	testosterone pellets	Y	N	N	N	N
J9329	Tevimbra	tislelizumab-jsgr		N	N	N	N
J2356	Tezspire	tezepelumab-ekko	Y	N	N	N	N
J9273	Tivdak	tisotumab vedotin-tftv		Y	N	N	N
J3590	Tocilizumab IV	tocilizumab-anoh		N	N	N	N
Q5156	Tocilizumab IV	tocilizumab-anoh		N	N	N	N
Q5133	Tofidence	tocilizumab-bavi		N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
Q5116	Trazimera	trastuzumab-qyyp		N	N	N	N
J3315	Trelstar	triptorelin pamoate	Y	N	N	N	N
J1628	Tremfya IV	guselkumab	Y	N	N	N	N
J3285	Treprostinil	treprostinil		N	N	N	N
J1443 J1444	Triferic	ferric pyrophosphate citrate		N	N	N	N
J1445	Triferic	ferric pyrophosphate citrate		N	N	N	N
J7332	Triluron	Sodium Hyaluronate		N	N	N	N
J3316	Triptodur	triptorelin	Y	N	N	N	N
J7329	Trivisc	hyaluronan or derivative		N	N	N	N
J9317	Trodelyv	sacituzumab govitecan-hziy		Y	N	N	N
J1746	Trogarzo	ibalizumab-uiyk	Y	N	N	N	N
Q5115	Truxima	rituximab-abbs		N	Y	N	N
Q5135	Tyenne IV	tocilizumab-aazg		N	N	N	N
Q5134	Tyruko	natalizumab-sztn	Y	N	N	N	N
J9381	Tzield	teplizumab-mzwv	Y	N	N	N	N
J1303	Ultomiris	ravulizumab-cwvz		Y	N	N	N
J9275	Unloxcyt	cosibelimab-ipdl		N	N	N	N
J1823	Uplizna	inebilizumab-cdon		Y	N	N	N
Q9999	ustekinumab-aauz IV	ustekinumab-aauz		N	N	N	N
Q9999	ustekinumab-aauz SQ	ustekinumab-aauz	Y	N	N	N	N
Q9998	Ustekinumab-AEKN IV	ustekinumab-aekn	Y	N	N	N	N
Q9998	Ustekinumab-AEKN SQ	ustekinumab-aekn	Y	N	N	N	N
Q5138	Ustekinumab-auub IV	ustekinumab-auub	Y	N	N	N	N
Q5137	Ustekinumab-auub SQ	ustekinumab-auub	Y	N	N	N	N
Q5099	ustekinumab-stba IV	ustekinumab-stba	Y	N	N	N	N
Q5099	ustekinumab-stba SQ	ustekinumab-stba	Y	N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ^{**}	PD-1 Wt Based Dosing ^{**}	IVIG Dose Optimization ^{**}
Q9997	Ustekinumab-ttwe IV	ustekinumab-ttwe	Y	N	N	N	N
Q9996	Ustekinumab-ttwe SQ	ustekinumab-ttwe	Y	N	N	N	N
J9217	Vabrinty	leuprolide depot	Y	N	N	N	N
Q5129	Vegzelma	bevacizumab-adcd		N	Y	N	N
J9041	Velcade	bortezomib		N	N	N	N
J9376	Veopoz	pozelimab-bbfg		Y	N	N	N
J1427	Viltepsa	viltolarsen	Y	Y	N	N	N
J1322	Vimizim	elosulfase alfa		Y	N	N	N
J7321	Visco-3	hyaluronan or derivative		N	N	N	N
J3385	Vpriv	velaglucerase alfa		N	N	N	N
J3032	Vyepti	eptinezumab-jjmr		N	N	N	N
J1326	Vyloy	zolbetuximab-clzb		N	N	N	N
J1429	Vyondys-53	golodirsen	Y	Y	Y	N	N
J9332	Vyvgart	efgartigimod alfa-fcab		Y	N	N	N
J9334	Vyvgart Hytrulo	efgartigimod alfa-fcab and hyaluronidase-qvfc		Y	N	N	N
J9153	Vyxeos	daunorubicin; cytarabine liposomal		N	N	N	N
Q5138	Wezlana IV	ustekinumab-auub	Y	N	N	N	N
Q5137	Wezlana SQ	ustekinumab-auub	Y	N	N	N	N
Q5136	Wyst	denosumab-bbdz	Y	N	N	N	N
Q5159	Xbryk	denosumab-dssb	Y	N	N	N	N
J1558	Xembify	subcutaneous immune globulin	Y	N	N	N	Y
J0218	Xenpozyme	olipudase alfa-rpcp		Y	N	N	N
J0588	Xeomin	incobotulinumtoxina	Y	N	N	N	N
J0897	Xgeva	denosumab	Y	N	N	N	N
J2357	Xolair	omalizumab	Y	N	N	N	N

Medical Specialty Medications

MassHealth - Prior Authorization List

Effective 04/01/2026

HCPCS	Brand Name	Generic Name	Dual Benefit	HCT ⁺	DW Program ⁺⁺	PD-1 Wt Based Dosing ⁺⁺	IVIG Dose Optimization ⁺⁺
J7354	Ycanth	cantharidin		N	N	N	N
J9228	Yervoy	ipilimumab		N	Y	N	N
Q5100	Yesintek IV	ustekinumab-kfce	Y	N	N	N	N
Q5100	Yesintek SQ	ustekinumab-kfce	Y	N	N	N	N
J1599	Yimmugo	intravenous immune globulin		N	N	N	Y
Q5141	Yuflyma	adalimumab-aaty	Y	N	N	N	N
J3590	Yusimry	adalimumab-aqvh	Y	N	N	N	N
J9400	Zaltrap	ziv-aflibercept		N	Y	N	N
J9223	Zepzelca	lurbinectedin		N	N	N	N
J9276	Ziihera	zanidatamab		N	N	N	N
J3304	Zilretta	triamcinolone acetone		N	N	N	N
Q5118	Zirabev	bevacizumab-bvzr		N	Y	N	N
J9202	Zoladex	goserelin acetate implant		N	N	N	N
J9999	Zusduri	mitomycin		N	N	N	N
J1748	Zymfentra	infliximab-dyyb	Y	N	N	N	N
J9359	Zynlonta	loncastuximab tesirine-lpyl	Y	N	N	N	N
J9345	Zynyz	retifanlimab-dlwr		N	N	N	N

*Please see November Provider Newsletter for program descriptions. ++Program is voluntary